FDA Approved: EGRIFTA WR — Supplemental Application (Theratechnologies Inc.)

View source ↗

Summary

FDA approved a supplemental application for EGRIFTA WR (tesamorelin) submitted by Theratechnologies Inc., indicating an additional FDA action on this product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hiv-associated Lipodystrophy

Drugs mentioned

• EGRIFTA WR (TESAMORELIN)

Snippet

SUPPL AP for EGRIFTA WR (TESAMORELIN)